The company is marketing the drug as a replacement to Roche’s tocilizumab (originally approved for rheumatoid arthritis) that is currently in off-label use among Covid-19 patients who suffer from cytokine release syndrome (CRS).
Copyright © 2024 | WordPress Theme by MH Themes